Galardi F - Search Results

1

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A. Pestrin M, et al. Among authors: galardi f. Breast Cancer Res Treat. 2009 Dec;118(3):523-30. doi: 10.1007/s10549-009-0461-7. Epub 2009 Jul 12. Breast Cancer Res Treat. 2009. PMID: 19597704

2

Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Oakman C, et al. Among authors: galardi f. Breast Cancer Res. 2009;11(2):205. doi: 10.1186/bcr2238. Epub 2009 Apr 3. Breast Cancer Res. 2009. PMID: 19435470 Free PMC article. Review.

3

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A. Oakman C, et al. Among authors: galardi f. Cancer Treat Rev. 2009 Dec;35(8):662-7. doi: 10.1016/j.ctrv.2009.08.006. Epub 2009 Sep 15. Cancer Treat Rev. 2009. PMID: 19758759 Review.

4

Adjuvant systemic treatment for individual patients with triple negative breast cancer.

Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L, Di Leo A. Oakman C, et al. Among authors: galardi f. Breast. 2011 Oct;20 Suppl 3:S135-41. doi: 10.1016/S0960-9776(11)70311-3. Breast. 2011. PMID: 22015281 Free article. Review.

5

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients.

Galardi F, Oakman C, Truglia MC, Cappadona S, Biggeri A, Grisotto L, Giovannelli L, Bessi S, Giannini A, Biganzoli L, Santarpia L, Di Leo A. Galardi F, et al. Breast. 2012 Jun;21(3):336-42. doi: 10.1016/j.breast.2012.02.007. Epub 2012 Mar 8. Breast. 2012. PMID: 22406214 Free article.

6

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A. Moretti E, et al. Among authors: galardi f. Future Oncol. 2013 Oct;9(10):1477-87. doi: 10.2217/fon.13.103. Future Oncol. 2013. PMID: 24106899

7

Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.

Oakman C, Pestrin M, Bessi S, Galardi F, Di Leo A. Oakman C, et al. Among authors: galardi f. Cancers (Basel). 2010 Jun 8;2(2):1221-35. doi: 10.3390/cancers2021221. Cancers (Basel). 2010. PMID: 24281114 Free PMC article.

8

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Turner N, et al. Among authors: galardi f. Cancers (Basel). 2014 Mar 25;6(2):684-707. doi: 10.3390/cancers6020684. Cancers (Basel). 2014. PMID: 24670368 Free PMC article.

9

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.

Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P. Pestrin M, et al. Among authors: galardi f. Mol Oncol. 2015 Apr;9(4):749-57. doi: 10.1016/j.molonc.2014.12.001. Epub 2014 Dec 9. Mol Oncol. 2015. PMID: 25539732 Free PMC article.

10

Using CTCs for pharmacogenomic analysis.

Hart CD, Galardi F, Pestrin M, De Luca F, Risi E, Di Leo A. Hart CD, et al. Among authors: galardi f. Pharmacol Res. 2016 Apr;106:92-100. doi: 10.1016/j.phrs.2016.02.019. Epub 2016 Feb 24. Pharmacol Res. 2016. PMID: 26921662 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters